GLP1 News and Research

RSS

Medicare prescriptions for Wegovy spike after heart disease coverage expansion

Medicare prescriptions for Wegovy increased sharply after the program started covering the anti-obesity medication to prevent heart problems, but just a fraction of beneficiaries likely eligible received the treatment, according to new research from the USC Schaeffer Center for Health Policy & Economics.

9 Jul 2026

GLP-1 medications may improve long-term health for people with peripheral artery disease

GLP-1 receptor agonists (GLP-1 RA) medications were shown to reduce the number of deaths, amputations and hospitalizations among people with Type 2 diabetes who also had narrowed leg arteries associated with PAD (peripheral artery disease), according to new, independent research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

1 Jul 2026

GLP-1 therapy associated with more dizziness and fainting

Northwestern Medicine scientists have identified a safety concern associated with GLP-1 drugs. Using health record data, the research team tracked more than 42,000 adults already taking at least two types of blood pressure medications.

14 Jun 2026

Positional therapy trains sleep apnea patients for long-term recovery

Positional therapy can be a long-lasting and effective treatment for patients with positional obstructive sleep apnea (OSA), according to research presented at the 2026 ATS International Conference.

20 May 2026

Early CPAP nonadherence does not predict long-term treatment failure

Many insurers stop covering continuous positive airway pressure or CPAP devices if patients don't use them regularly in the first 90 days.

20 May 2026

GLP-1 weight loss medications linked to significant drop in asthma flares

New research presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26 % fall in the number of asthma exacerbations and a 14% drop in use of asthma inhaler reliever use. The study is by Simon Høj and Dr Kjell Erik Julius Håkansson, Copenhagen University Hospital, Copenhagen, Denmark and colleagues.

15 May 2026

Adding GLP-1 drugs to behavioral interventions silences food noise

New research presented at this year's European Congress on Obesity in Istanbul, Turkey, shows that use of obesity drugs alongside behavioral interventions leads to a larger drop in so called 'food noise' than in those using the behavioral therapy alone.

13 May 2026

Semaglutide improves liver function independently of weight loss

Researchers at Toronto's Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1 – acts directly on a subset of liver cells to improve organ function and does so independently of weight loss.

15 Apr 2026

Study finds nutritional risks in users of GLP-1 drugs

Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.

9 Apr 2026

Study finds genetic basis for GLP-1 weight loss efficacy and side effects

23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects.

8 Apr 2026

Taking a GLP-1? Doctors say not to forget about movement and mental health

Severe ankle pain drove Jelon Smart to start taking a weight loss injection a year and a half ago.

26 Mar 2026

Python blood compound could lead to new weight loss therapies

University of Colorado Boulder researchers have discovered an appetite-suppressing compound in python blood that helps the snakes consume enormous meals and go months without eating yet remain metabolically healthy.

19 Mar 2026

Brain circuit links past experiences to appetite control

Our past experiences shape how much we eat and where and what we choose to eat. Using preclinical models, researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified brain cells that translate contextual information into appetite control.

12 Feb 2026

Diabetes drug use linked to fewer gout treatments

Natalie McCormick, PhD, of the Rheumatology and Allergy Clinical Epidemiology Research (RACER) Center within the Division of Rheumatology in the Mass General Brigham Department of Medicine, is the lead author of a paper published in Diabetes Care, "Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies."

2 Feb 2026

New trial tests strategies to protect heart health during prostate cancer therapy

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.S. News & World Report, has opened a phase 2 clinical trial comparing three different strategies for protecting heart health in prostate cancer patients who receive androgen deprivation therapy (ADT), a potentially lifesaving hormone therapy.

26 Jan 2026

California ends Medicaid coverage of weight loss drugs despite TrumpRx plan

Many low-income Californians prescribed wildly popular weight loss drugs lost their coverage for the medications at the start of the new year.

9 Jan 2026

WHO reviews highlight limited long-term data on GLP-1 drug safety

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity.

30 Oct 2025

GLP-1 drugs like Ozempic may slow how quickly alcohol hits the bloodstream

Preliminary study shows GLP-1 receptor agonists alter alcohol response, suggesting potential for reducing cravings and intoxication in obese individuals.

17 Oct 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight.

15 Sep 2025